Literature DB >> 27036977

Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis.

John Raffalli1, Gary P Wormser2.   

Abstract

We report a patient who was being treated with rituximab for rheumatoid arthritis who developed Babesia microti infection that persisted for 26 months despite prolonged anti-babesia drug therapy. The explanation for the persistence was likely to have been the long-term immunocompromising effects of rituximab, as evidenced by seronegativity for B. microti antibodies that lasted for more than 1 year after onset of infection.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Babesia microti; Babesiosis; Rituximab

Mesh：

Substances：

Year:  2016        PMID： 27036977     DOI： 10.1016/j.diagmicrobio.2016.02.016

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  20 in total

Review 1.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

Review 2.  Babesia microti: from Mice to Ticks to an Increasing Number of Highly Susceptible Humans.

Authors:  Lars F Westblade; Matthew S Simon; Blaine A Mathison; Laura A Kirkman
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

3.  Elimination of Babesia microti Is Dependent on Intraerythrocytic Killing and CD4+ T Cells.

Authors:  Sini Skariah; Paul Arnaboldi; Raymond J Dattwyler; Ali A Sultan; Corey Gaylets; Odaelys Walwyn; Hannah Mulhall; Xia Wu; Soha R Dargham; Dana G Mordue
Journal:  J Immunol       Date:  2017-06-12       Impact factor: 5.422

4.  Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?

Authors:  Dana G Mordue; Gary P Wormser
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

5.  Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.

Authors:  Matthew S Simon; Lars F Westblade; Alexis Dziedziech; Joseph E Visone; Richard R Furman; Stephen G Jenkins; Audrey N Schuetz; Laura A Kirkman
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

Review 6.  Investigating disease severity in an animal model of concurrent babesiosis and Lyme disease.

Authors:  Purnima Bhanot; Nikhat Parveen
Journal:  Int J Parasitol       Date:  2018-10-24       Impact factor: 3.981

7.  Robust adaptive immune response against Babesia microti infection marked by low parasitemia in a murine model of sickle cell disease.

Authors:  Woelsung Yi; Weili Bao; Marilis Rodriguez; Yunfeng Liu; Manpreet Singh; Vijendra Ramlall; Jeny R Cursino-Santos; Hui Zhong; Catherine M Elton; Gavin J Wright; Avital Mendelson; Xiuli An; Cheryl A Lobo; Karina Yazdanbakhsh
Journal:  Blood Adv       Date:  2018-12-11

8.  Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone.

Authors:  Lauren A Lawres; Aprajita Garg; Vidya Kumar; Igor Bruzual; Isaac P Forquer; Isaline Renard; Azan Z Virji; Pierre Boulard; Eduardo X Rodriguez; Alexander J Allen; Sovitj Pou; Keith W Wegmann; Rolf W Winter; Aaron Nilsen; Jialing Mao; Douglas A Preston; Alexia A Belperron; Linda K Bockenstedt; David J Hinrichs; Michael K Riscoe; J Stone Doggett; Choukri Ben Mamoun
Journal:  J Exp Med       Date:  2016-06-06       Impact factor: 14.307

9.  Babesia microti Infection Changes Host Spleen Architecture and Is Cleared by a Th1 Immune Response.

Authors:  Vitomir Djokic; Lavoisier Akoolo; Nikhat Parveen
Journal:  Front Microbiol       Date:  2018-01-31       Impact factor: 5.640

10.  Autoimmune hemolytic anemia associated with babesiosis.

Authors:  Roshni Narurkar; Aleksandra Mamorska-Dyga; John C Nelson; Delong Liu
Journal:  Biomark Res       Date:  2017-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.